



Figure 1




100004219, 060302

Figure 2



10004219 060202


Figure 3



TITLE: A MAMMALIAN MUCINASE, ITS RECOMBINANT
PRODUCTION, AND ITS USE IN THERAPY OR
PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS
INVOLVED OR INFECTION DISEASES

Inventor: Aerts et al.
Serial No. 10/004,219

Figure 4



B



	pH2	pH7
h-chitotriosidase	0%	100%
m-AMCase	108%	98%

C

TCA(%)	0.5	1.25	2.5	5.0
h-chitotriosidase	58%	74%	97%	100%
m-AMCase	0%	8%	74%	100%

TITLE: A MAMMALIAN MUCINASE, ITS RECOMBINANT PRODUCTION, AND ITS USE IN THERAPY OR PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS INVOLVED OR INFECTION DISEASES

Inventor: Aerts et al.
Serial No. 10/004,219



Lymphnode
Lung
Liver
Colon
stomach
Small Intestine

B
Figure 5

TITLE: A MAMMALIAN MUCINASE, ITS RECOMBINANT
PRODUCTION, AND ITS USE IN THERAPY OR
PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS
INVOLVED OR INFECTION DISEASES

Inventor: Aerts et al.
Serial No. 10/004,219





Figure 6

TITLE: A MAMMALIAN MUCINASE, ITS RECOMBINANT
PRODUCTION, AND ITS USE IN THERAPY OR
PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS
INVOLVED OR INFECTION DISEASES

Inventor: Aerts et al.
Serial No. 10/004,219



Figure 7



TITLE: A MAMMALIAN-MUCINASE, ITS RECOMBINANT
PRODUCTION, AND ITS USE IN THERAPY OR
PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS
INVOLVED OR INFECTION DISEASES

Inventor: Aerts et al.
Serial No. 10/004,219

Figure 8. From top to bottom: amino acid sequence (m) AMCase (SEQ ID NO:9), (h) AMCase (SEQ ID NO:14) and (h) chitotriosidase (SEQ ID NO:10). Residues conserved among at least two out of the three sequences are in bold.

```
1  YNLICYFTNWAQYRPGLGSFKPDDINPCLCTHLIYAFAGMQNN 43
1  YQLTCYFTNWAQYRPGLGRFMPDNIDPCLCTHLIYAFAGRQNN 43
1  AKLVCYFTNWAQYRQGEARFLPKDLDPCLCTHLIYAFAGMTNH 43

44  EITTIEWNDVTLYKAFNDLKNRNSKLKTLLAIGGWNFGTAPF 85
44  EITTIEWNDVTLYQAFNGLKNKNSQLKTLLAIGGWNFGTAPF 85
44  QLSTTEWNETLYQEFNGLKKMNPKLKTLLAIGGWNFGTQKF 85

86  TTMVSTSQNRQTFITSVIKFLRQYGF DGLDLDWEYPGSRGSPP 128
86  TAMVSTPENRQTFITSVIKFLRQYEF DGLDFDWEYPGSRGSPP 128
86  TDMVATANNRQTFVNSAIRFLRKYSF DGLDLDWEYPGSQGSPA 128

129 QDKHLFTVLVKEMREAFEQEAEIESNRPLMVTA AVAGGISNIQ 171
129 QDKHLFTVLVQEMREAFEQEAKQINKPRLMVTA AVAAGISNIQ 171
129 VDKERFTTLVQDLANAFQQAQTSGKERLLLSAAVPAGQTYVD 171

172 AGYEIPELSKYLD FFIHVMTYDLHGSGWEGYTGENSPLYKYPT E 213
172 SGYEIPQLSQYLDYIHVMTYDLHGSGWEGYTGENSPLYKYPT D 213
172 AGYEVDKIAQNLD FVNL MAYDFHGSWEKVTGHNSPLYKRQE E 213

214 TGSNAYLNVDYVMNYWKNNGAPA EKLIVGFPEYGH TFI LRNPS 256
214 TGSNAYLNVDYVMNYWKDNGAPA EKLIVGFPT YGHNFILSNPS 256
214 SGAAASLNVDAAVQQWLQK GTPASKLILGMPT YGRSFTLASS S 256

257 DNGIGAPTSGDGPAGAYTRQAGFWAYYEICTFLRSGATEVWDA 299
257 NTGIGAPTSGAGPAGPYAKESGIWAYYEICTFLKNGATQGWD A 299
257 DTRVGAPATGSGTPGPFTKEGGMLAYYEVC SW - -KGATKQRIQ 297

300 SQEVPYAYKAN EWLGYDNIKSFSVKAQWLKQNNFGGAMIWAID 342
300 PQEVPYAYQGNVWVG YDNIKSFDIKAQWLKHNKFGGAMVWAID D342
300 QVPYIFRDNQWVG FDDVESFKTKVSYLKQKGLGGAMVWALD 340

343 LDDFTGSFCDQ GK FPLTSTLNKALGISTEGCTAPDVPSEPVT T - 385
343 LDDFTGTFCNQ GK FPLISTLK KALGLQSASCTAPAQPIEPITAA 386
341 LDDFAGFSCNQGRYPLIQTLRQELSLPYLPSGTPEL-EVPKPGQ 383

386 - -PPGSGSGGGSSGGSSGGSGGFCADKADGLYPVADDRNAFWQC 426
387 PSGSGNGSGSSSSGGSSGGSGGFC AVRANGLYPVANNRNAFWHC 429
384 PS - - - - -EPEHG PSPG'QDTFCQGKADGLYPNPRERSSFYSC 419

INGITYQQHCQAGLVFD TSCNCCNWP 452
VNGVTYQQNCQAGLVFD TSCDCCNWA 455
AAGRLFQQSCPTGLVFS NSCKCCTWN 445
```